Introduction {#s1}
============

Hypospadias is defined as a malformation of the penis due to an incomplete development of the ventral part of the penis. This may include (1) a defect in the developing urethra leading to the localization of the urinary meatus on the ventral aspect of the penis in a variable position from the glans to the perineum [@pone.0061824-Leung1], (2) a defect in the ventral part of the prepuce, and (3) an inconstant ventral penile curvature mainly related to a defect in the ventral skin or, more rarely, the development of the corpus cavernosum. Hypospadias is the second most common congenital malformation in males, occurring in approximately 1 in 125 live male births [@pone.0061824-Manson1]. In addition to the surgical challenge of correcting this malformation and reducing the non-negligible risk of complications, the clinical challenge today is to elucidate the pathophysiology. A better understanding would optimize childhood management, guide the follow-up of these children to adulthood, and predict those patients at risk of fertility problems in adult life. Unfortunately, the exact etiology remains unknown and is not even sought in most cases, especially anterior isolated hypospadias without any other signs of disorders of sex development such as micropenis or cryptorchidism.

Androgens play a central role in male external genital development. Testosterone and its derivative 5 alpha-dihydrotestosterone are the two major androgens that mediate male sexual differentiation, and an alteration in the androgen sensitivity pathway has been identified in undermasculinized boys [@pone.0061824-Philibert1]. Extensive mutation screening in hypospadiac patients has revealed disease-associated sequence alterations, predominantly in the *AR*. These mutations are usually found in partial or complete androgen insensitivity syndrome [@pone.0061824-Philibert1], [@pone.0061824-Sultan1]. *AR* sequencing is thus generally performed in selected patients with severe 46,XY DSD with normal or elevated plasma level of testosterone [@pone.0061824-Deeb1], but *AR* mutations are usually not considered as a cause of isolated hypospadias [@pone.0061824-Nordenskjold1]--[@pone.0061824-Wang1], the most minor form of DSD.

It is nevertheless now emerging that many milder variants of the classic disorders exist, especially in partial androgen insensitivity syndrome. Moreover, a systematic approach to genetic analysis is providing rewards in some cases [@pone.0061824-Wang1], [@pone.0061824-Silver1]. The aim of this study was to determine whether isolated hypospadias, including the most minor forms, is associated with *AR* mutations and thus whether all types of hypospadias should warrant molecular analysis of the *AR*.

Materials and Methods {#s2}
=====================

Patients {#s2a}
--------

In this study, 292 Caucasian boys presenting with isolated hypospadias (no micropenis, no cryptorchidism) were included prospectively (newborn to 12 years). Clinical diagnosis was performed by direct clinical examination by the pediatric urologist or pediatric endocrinologist. The location of the urethral meatus ranged from glandular to perineal hypospadias (glandular and penile anterior n = 190, midshaft n = 61, penile posterior n = 28, penoscrotal and perineal n = 13). The level of division of the corpus spongiosum---which can be assessed during degloving of the penis at the time of surgical correction---was not used as a classification method here since some patients with anterior and glandular hypospadias did not undergo surgery. Three hundred and forty-five controls alleles were sequenced. They included 245 normospermic men \[the definition of normospermic is ≥20×10^6^ ml sperm concentration, ≥40×10^6^ total sperm count, ≥2 ml semen volume, ≥50% of a+b or ≥25% motility and a high percentage of normal forms (≥10%) according to the WHO criteria\], with normal location of the urethral meatus, noncleaved prepuce and intrascrotal testis, and 50 women of known fertility (more than 2 normal children). This study was approved by the Institutional Review Board of the institution (Centre de Protection des Personnes Sud Méditerannée 4, CPPSMIV, ID RCB n° 2008-A00781-54) and written consent was obtained from all parents.

DNA extraction {#s2b}
--------------

DNA was extracted from either peripheral blood or preputial skin. When blood was used, the DNA was extracted with a QIAamp DNA blood minikit (Qiagen, Courtaboeuf, France). When tissue was used, the excess skin removed at the time of hypospadias surgery and/or circumcision was frozen in liquid nitrogen. DNA was extracted from this tissue using DNAzol (Invitrogen). The manufacturer\'s protocol for DNA isolation was followed with minor modifications.

Mutational analysis {#s2c}
-------------------

After polymerase chain reaction (PCR) amplification of exons 1--8 of the *AR* using the Taq PCR Master Mix kit from Qiagen (Courtaboeuf, France), we performed direct sequencing using the BigDye terminator v1.1 kit (Applied Biosystems, Foster City, CA) and an ABI Prism310 Genetic Analyzer (Applera, Courtaboeuf, France), as reported elsewhere [@pone.0061824-Philibert1]. In cases of mutation, PCR and sequencing of the DNA sample were repeated twice to confirm the finding and rule out any PCR-generated errors. Every PCR product was sequenced with forward and reverse primers. When *AR* mutations were detected, *SRD5A2* and *MAMLD1* genes were also sequenced to rule out another cause of hypospadias [@pone.0061824-Maimoun1],[@pone.0061824-Kalfa1]. The amino acid numbering for the AR was based on the NCBI reference sequence [NM_000044.2]{.ul} and the AR database [@pone.0061824-Gottlieb1].

Homology study and structure prediction {#s2d}
---------------------------------------

When a mutation that had never been reported was found, the functional consequences of amino acid changes were predicted using in silico models.

Regarding the homology study, ensembl.org detected the putative homologs of the human *AR* gene and alignments were made with the ClustalW software at <http://www.ebi.ac.uk/Tools/msa/clustalw2/>.

Regarding the structure prediction, the secondary structure for wildtype and variants was predicted using JPred software [@pone.0061824-Cole1] (<http://www.compbio.dundee.ac.uk/www-jpred/>). The relative accessibility of amino acids was studied with Netsurf software [@pone.0061824-Petersen1] (<http://www.cbs.dtu.dk/services/NetSurfP/>). The three-dimensional structure was predicted by the Protein Homology/analogY Recognition Engine (PhyreEngine) from the Structural Bioinformatics Group, Imperial College, London, at <http:www.sbg.bio.ic.ac.uk/phyrew/> [@pone.0061824-Kelley1].

The functional consequences of amino acid changes were predicted using three algorithms. Polyphen (Harvard, USA) ([@pone.0061824-Ramensky1], [@pone.0061824-Thomas1], Panther {Mi, 2010 \#86) and Sift (University of British Columbia) [@pone.0061824-Kumar1] were used, respectively, at <http://genetics.bwh.harvard.edu/pph/>, <http://www.pantherdb.org/tools/csnpScoreForm.jsp>., and <http://sift.jcvi.org/>. These algorithms are based on the alignment of orthologous and/or paralogous protein sequences and/or structural constraints.

Plasmids {#s2e}
--------

The full-length AR expression construct pSVAR0 was a kind gift of Dr. A. Brinkmann (Rotterdam, NL). The pAR-D551H mutant was constructed by site-directed mutagenesis in a two-step PCR using pSVAR0 as a template. In the first round, the primer pair AR-Kpn_fwd: 5′-CGC ACC TGA TGT GTG GTA CCC T and the mutagenesis primer AR-g1651_as: 5′- GTG GAA AGT AAT AGT GAA TGG GCA AAA CAT GGT CCC T were used in PCR1 and AR-g1651c_s: 5′- AGG GAC CAT GTT TTG CCC ATT CAC TAT TAC TTT CCA C and hARE4a: 5′-ACT ACA CCT GGC TCA ATG GC were used in PCR2. Both amplicons were gel-purified, denatured, annealed and amplified in a second round using primer pair AR-Kpn_fwd and hARE4a. The resulting amplicon was digested with *Kpn*I and *Tth*111I and subcloned into the respective sites of pSVAR0. The construct was verified by sequencing the insert and cloning borders. The PEM-luc firefly luciferase reporter construct containing the proximal promoter of the mouse *Rhox5* gene was a kind gift of Dr. F. Claessens (Leuven, Belgium). The Renilla luciferase construct phRG-TK was obtained from Promega, WI, Madison, USA.

Cell culture and transfections {#s2f}
------------------------------

Hela cells were maintained in Dulbecco\'s modified Eagle\'s medium/Ham\'s nutrient mixture F-12 (DMEM, Sigma) supplemented with 10% fetal calf serum in 5% CO2 at 37°C.

For transfection, HeLa cells were seeded at 50,000 cells per well in 24-well plates in DMEM medium supplemented with 10% charcoal-stripped fetal calf serum. After 24 hr, cells were transfected with 200 ng of *Rhox5* firefly-luciferase reporter plasmid, 30 ng AR expression plasmid, 10 ng of the constitutive Renilla luciferase expression plasmid phRG-TK, and 0.72 µl Fugene HD (Promega, Madison, WI, USA) per well. Five hours post-transfection, cells were incubated for 18 hr with either vehicle or the indicated concentration DHT, Firefly and Renilla luciferase activities were detected using the Dual-Luciferase reporter assay kit (Promega, Madison, WI, USA) and a LUCY 3 Luminometer (Anthos, Krefeld, Germany). The activity of the Renilla luciferase was used to normalize for transfection efficiency. All transfections were performed in triplicate and in at least 3 independent experiments.

Results {#s3}
=======

Five missense mutations of the *AR* were identified in 9 of the 292 patients, i.e., 3%: p.Q58L (c.173A\>T), 4 cases of p.P392S (c.1174C\>T), 2 cases of p.A475V (c.1424C\>T), p.D551H (c.1651 G\>C) and p.Q799E (c.2395C\>G). None of these mutations was present in the control group. The hypospadias was not severe in 5 cases (glandular and penile anterior n = 5, penile midshaft n = 2) and penile posterior in 2 cases only. Clinical data are summarized in [Table 1](#pone-0061824-t001){ref-type="table"}. Exon 1 was the most frequent mutated exon in this series (n = 7/9). No mutation of *SRD5A2* or *MAMLD1* was found in these patients. The mothers were not available for sequencing.

10.1371/journal.pone.0061824.t001

###### Clinical and hormonal data of patients with mutated *AR*.

![](pone.0061824.t001){#pone-0061824-t001-1}

                                                                p.Q58L (c.1288A\>T)   p.P392S (c.2289 C\>T)                                        p.P392S (c.2289 C\>T)                                                                      p.P392S (c.2289 C\>T)                                 p.P392S (c.2289 C\>T)   p.A475V (c.2539 C\>T)   p.A475V (c.2539 C\>T)   p.D551H (c.1651 G\>C)                                p.Q799E (c.3510 C\>G)
  ------------------------------------------------------------ --------------------- ----------------------- ------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- ----------------------- ----------------------- ----------------------- ----------------------- ----------------------------------------------------------------------------------
  **Medical history**                                                                                                                                                                                                                                                                                                                                                                              
  Familial history of genital malformation                              No                     No             Yes, penile hypospadias in brother and cousin on maternal side[\*](#nt101){ref-type="table-fn"}                                          No                                                    No                      No                      No                      No             Yes, penile hypospadias in uncle, maternal side[\*](#nt101){ref-type="table-fn"}
  Maternal exposure to endocrine disruptors during pregnancy            No                     No                                                           No                                                                                         No                                                    No                      No                      No                Yes, pesticides                                             No
  Term of birth (weeks of amenorrhea)                                   41                     39                                                           40                                                                                         39                                                    41                      41                      40                      37                                                    41
  Birth weight of (kg)                                                  3.8                    4.1                                                          2.7                                                                                        3.1                                                   3.0                     3.7                     3.6                     3.3                                                  3.2
  **Phenotype**                                                                                                                                                                                                                                                                                                                                                                                    
  Age (years, months)                                                1 y, 7 m               5 y, 6 m                                                     4 y, 4 m                                                                                   11 y, 9 m                                             3 y, 7 m                0 y, 7 m                0 y, 7 m                 1 week                                               0 y, 6 m
  Weight (kg)                                                           12                     24                                                           16                                                                                         41                                                    16                      8.5                     8.4                     3.3                                                   8
  Height (cm)                                                           83                     118                                                          NA                                                                                         152                                                   NA                      74                      71                      48                                                    68
  Meatus topography                                                  Glandular              Glandular                                                 Penile midshaft                                                                           Penile posterior                                          Glandular            Penile anterior         Penile midshaft         Penile anterior                                      Penile posterior
  Testis position                                                  Intrascrotal           Intrascrotal                                                 Intrascrotal                                                                               Intrascrotal                                          Intrascrotal            Intrascrotal            Intrascrotal            Intrascrotal                                          Intrascrotal
  Penile length (mm)                                                    33                     45                                                           35                                                                                         33                                                    45                      35                      50                      32                                                    32
  Other malformations                                                   No                     No                                                           No                                                  High anorectal malformation, right vesicoureteral reflux and mitral insufficiency            No                      No                      No                      No                                                    No
  **Hormonal work up**                                                                                                                                                                                                                                                                                                                                                                             
  Age at hormonal work-up                                            1 y, 7 m               5 y, 6 m                                                     4 y, 4 m                                                                                   11 y, 9 m                                             3 y, 7 m                0 y, 7 m                0 y, 7 m                 1 week                                               0 y, 6 m
  FSH (UI/l) (1--10 UI/l)                                              0.11                   0.79                                                         0.11                                                                                       0.37                                                  0.13                    0.69                     NA                      NA                                                   0.63
  LH(UI/l) (1--12 UI/l)                                                 NA                     0.1                                                         0.43                                                                                       1.73                                                  0.467                   0.32                     NA                      NA                                                   2.87
  Testosterone (ng/ml) (1--3 ng/ml)                                    \<0.1                  \<0.1                                                        \<0.1                                                                                      2.26                                                  \<0.1                   \<0.1                   0.55                      1                                                   1.74

Family relatives declined genetic examination. NA: not available. Parentheses indicate the normal range for hormone serum levels.

The p.D551H (c.1651 G\>C) mutation has never been described and was thus tested in silico.

The secondary structure was predicted to be modified proximal to the mutation with changes in a helical domain of 11 amino acids. The relative and absolute accessibilities of the amino acid were modified from 0.55 to 0.60 and from 77.06 to 110.41, respectively. The structure prediction of the mutated protein was significantly changed (data not shown). All 3 in silico algorithms predicted affected protein function (Polyphen: probably damaging with a 0.99 score; Sift: damaging with a 0.0 score; and Panther: probably a deleterious effect with a 0.79 score) with a conserved amino acid throughout species ([table 2](#pone-0061824-t002){ref-type="table"}).

10.1371/journal.pone.0061824.t002

###### Homology study showed that this amino acid was highly conserved through species for the c.1651G\>C mutation.

![](pone.0061824.t002){#pone-0061824-t002-2}

  ------------ -------------------------------
  Patient       LETARDHVLPI **H** YYFPPQKTCLI
  Human-AR      LETARDHVLPI **D** YYFPPQKTCLI
  Pig           LEPTRDHVLPI **D** YYFPPQKTCLI
  Chimpanzee    LETARDHVLPI **D** YYFPPQKTCLI
  Mouse         LDSTRDHVLPI **D** YYFPPQKTCLI
  Rabbit        LETARDHVLPI **D** YYFPPQKTCLI
  Dog           LETARDHVLPI **D** YYFPPQKTCLI
  Cat           LETSRDHVLPI **D** YYFPPQKTCLI
  ------------ -------------------------------

The in vitro functional studies confirmed that the D551H mutation induced a reduction of the androgen receptor transactivation. The difference between the wild type protein and the mutated one was significant at DHT concentrations between 0.01 and 10 nM ([Figure 1](#pone-0061824-g001){ref-type="fig"}).

![Relative luciferase units (RLU) of the wildtype androgen receptor (WT) and D551H protein and their curves of concentration-response.\
The D551H mutation significantly reduces the transactivation at DHT concentrations between 0.01 and 10 nM. T-test including equal variance test and was performed using Sigma Stat. \*: p = 0.38 ; \*\*: p\<0.001.](pone.0061824.g001){#pone-0061824-g001}

Discussion {#s4}
==========

The recommendations for the appropriate use of genetic testing in male children with genital malformation state that *AR* mutation analysis, along with karyotyping and hormonal work-up, should be performed in children with (1) a phenotype of uncertain sex at birth, (2) severe hypospadias, and (3) hypospadias associated with another sign of DSD that could be a manifestation of partial androgen insensitivity syndrome, such as micropenis or cryptorchidism [@pone.0061824-Edery1]. However, these recommendations have been based on limited data, and comprehensive studies of a large number of patients with minor hypospadias and complete sequencing of the *AR* including exon 1 remain rare. Vottero et al. [@pone.0061824-Vottero1] recently observed that the *AR* in target tissues from patients with hypospadias is more methylated than in control children, resulting in a decreased expression of the *AR*. However, no mutation was identified. In order to better elucidate the genotype-phenotype relation and identify which patients should be explored, we prospectively screened a large number of unselected hypospadiac subjects.

We found that 3% of 292 boys with isolated hypospadias had *AR* mutations. Two of these mutations have already been associated with severe genital malformation: p.Q799E [@pone.0061824-Bevan1], [@pone.0061824-Quigley1] and p.P392S [@pone.0061824-Hiort1]--[@pone.0061824-Audi1]. The 3 other mutations may represent novel findings since 1 has never been reported to date (p.D551H, c.1651 G\>C) and 2 have not been reported in patients with genital malformation but only isolated infertility: p.Q58L [@pone.0061824-Lund1], p.A475V [@pone.0061824-Zuccarello1], [@pone.0061824-Ferlin1]. It is notable that micropenis, a cardinal sign of PAIS, was not present in any patient.

The risk of infertility is known to be associated with hypospadias, but there has been no definitive and methodologically adequate study of the fertility of men born with hypospadias. In an evaluation of the social and sexual impact of this malformation, Aho et al. [@pone.0061824-Aho1] showed that adult men operated on for hypospadias in childhood had fewer children than controls (0.8 vs. 1.1). But multiple factors such as surgical results, psychological aspects and quality of ejaculation may have contributed to this observation. The semen of corrected hypospadiac patients (isolated or not) was tested by Bracka [@pone.0061824-Bracka1] and 30% of these patients had sperm counts below 20 million/ml. Unfortunately, the development of spermatogenesis in children born with hypospadias remains little documented due to the difficulty of long term follow-up, the absence of a univocal etiology of this malformation, and the multiplicity of factors that may influence male fertility. The association of hypospadias with other testicular developmental abnormalities, especially cryptorchidism, raises further questions about the future fertility of these patients. Cryptorchidism is more frequent in these patients than in the general population [@pone.0061824-Thonneau1], but the rate is similar to the 5% to 10% found in infertile men [@pone.0061824-Mieusset1].

Thus, the patients with the highest risk are mainly those with cryptorchidism and those with a severe meatus displacement [@pone.0061824-Asklund1]. In contrast, children with anterior and isolated hypospadias are thought to be as fertile as the general population. Our findings, along with the possibly altered hormonal work-up in these patients [@pone.0061824-Rey1], raise questions about this unproven dogma. Approximately 40% of the men with isolated hypospadias have a sperm concentration below 40 million/ml, which may indicate subfecundity [@pone.0061824-Slama1], [@pone.0061824-Guzick1]. A study reporting the histological aspect of testicular biopsies from 33 patients who had been operated on for hypospadias in childhood also point toward the risk of infertility in patients with isolated hypospadias [@pone.0061824-Jugenburg1]. Twenty-seven percent of them had an abnormal testicular histology suggesting low spermatogenesis, compared with 75% of patients with hypospadias and cryptorchidism. The finding of *AR* mutations even in the most minor forms of hypospadias may indicate that these mutations make up part of the common background of these two diseases. Early detection of the *AR* mutations known to be usually present in patients with PAIS syndromes or hypofertile men might also significantly improve (1) the hormonal and clinical follow-up of these patients during puberty, especially regarding the size of the penis. Indeed, the activities and effects of androgens during fetal life do not always predict their impact on penile growth during puberty [@pone.0061824-Dean1]; and (2) the information given to parents and patients: identifying the genetic origin of this malformation might help to provide adequate fertility information and genetic counseling for the daughters.

It is notable that 7 out of 9 patients exhibited a mutation in exon 1 of the *AR*, whereas about 85% of the mutations reported in the *AR* mutations database [@pone.0061824-Gottlieb2] (<http://www.mcgill.ca/androgendb/>) are localized in exons 2 to 8. In contrast, the mutations responsible for minor phenotypes, as seen in our series, are mainly present in exon 1. Of the exon 1 mutations described in the *AR* database, 70% induced complete androgen insensitivity syndrome (CAIS), 14% induced partial androgen insensitivity syndrome (PAIS), and 16% were implicated in infertility. Exon 1 is an important regulatory region for AR activity. It encodes the N-terminal domain of the AR protein, which contains transactivation elements, dimerization zones, several cofactor binding sites, and two regions (^25^FXXLF^27^ and ^433^WXXLF^437^) involved in N-terminal and C-terminal domain interactions. Loss of this domain results in inactivation of the AR since testosterone binding no longer leads to its conformational change and the subsequent interactions between helix H12 and helix H3 [@pone.0061824-He1]. Exon 1 mutations are thus mainly associated with CAIS. In a recent report by Philibert et al. [@pone.0061824-Philibert1], all these mutations led to a premature stop codon and totally disrupted AR transductional activity because the protein was truncated, explaining the severe phenotype. In our study, the phenotype was minor with isolated hypospadias and no nonsense mutation was identified. The functional studies of the D551H mutation demonstrating a slightly lowered transactivation of the receptor are in agreement with some level of genotype-phenotype correlation. Such a correlation has not been demonstrated for the AR and there are important variations in phenotypes for a single *AR* mutation in the database (ranging from PAIS to infertility). These results nevertheless show that missense mutations of exon 1 may slightly alter AR function, inducing minor phenotypes.

Isolated and minor hypospadias is the most frequent form of 46,XY DSD, and screening all patients with this phenotype would be very expensive and time-consuming. It would thus be helpful to identify the subgroup of these children who need to be screened for an *AR* mutation. In our series, no clinical data from the medical history or physical examination were able to identify patients at risk for these mutations. Mutated subjects had no other signs of androgen insensitivity than isolated hypospadias. Size of the penis, location of testes and location of the urethral meatus were unable to identify *a priori* patients with a higher risk of AR abnormalities. Familial history was more frequent in patients with an *AR* mutation (2/7) than in the others (28.5% vs 13%, p\>0.05), but this criterion is not sufficient and it misses most of the patients with a genetic alteration. The clinical data alone cannot be used as indicators of *AR* mutation. The hormonal work-up was of no help either. Although higher LH and testosterone concentrations are observed in patients with more severe forms of androgen insensitivity such as CAIS, measurements of LH, FSH and plasma testosterone were normal or inconclusive in our series since most patients with a minor phenotype are referred to the surgeon during infancy, far after the neonatal period of pituitary-testicular activity (mini-puberty). Conducting systematic HCG tests in these patients would be abusive.

Conclusion {#s5}
==========

*AR* mutations may play a role in the cause of isolated hypospadias, even in the most minor forms of this malformation. We found a prevalence of mutations of about 3%. These patients with AR abnormalities did not differ from the vast majority of hypospadiac boys. Identification of the underlying alteration in the *AR* may be important for a proper diagnosis of this frequent genital abnormality. Longer follow-up of these patients is necessary to determine whether these mutations cause differences in sexual function and fertility later in life.
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